Catriona Yale Sells 6,136 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) Stock

Akero Therapeutics, Inc. (NASDAQ:AKRO) insider Catriona Yale sold 6,136 shares of Akero Therapeutics stock in a transaction that occurred on Monday, October 14th. The shares were sold at an average price of $30.03, for a total transaction of $184,264.08. Following the completion of the sale, the insider now owns 74,158 shares of the company’s stock, valued at approximately $2,226,964.74. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

Catriona Yale also recently made the following trade(s):

• On Friday, September 20th, Catriona Yale sold 5,500 shares of Akero Therapeutics stock. The stock was sold at an average price of $27.65, for a total value of $152,075.00.
• On Wednesday, September 18th, Catriona Yale sold 3,871 shares of Akero Therapeutics stock. The shares were sold at an average price of $27.56, for a total value of $106,684.76.
• On Monday, September 16th, Catriona Yale sold 2,485 shares of Akero Therapeutics stock. The shares were sold at an average price of $27.52, for a total value of $68,387.20.
• On Tuesday, September 10th, Catriona Yale sold 637 shares of Akero Therapeutics stock. The stock was sold at an average price of $26.18, for a total transaction of $16,676.66.
• On Friday, August 23rd, Catriona Yale sold 8,851 shares of Akero Therapeutics stock. The shares were sold at an average price of $27.53, for a total transaction of $243,668.03.
• On Monday, August 26th, Catriona Yale sold 5,200 shares of Akero Therapeutics stock. The stock was sold at an average price of $27.51, for a total transaction of $143,052.00.

Akero Therapeutics Trading Down 0.7 %

Shares of AKRO stock opened at $30.82 on Friday. The company has a quick ratio of 24.89, a current ratio of 24.89 and a debt-to-equity ratio of 0.04. The firm has a market capitalization of $2.13 billion, a P/E ratio of -9.63 and a beta of -0.25. Akero Therapeutics, Inc. has a twelve month low of $11.25 and a twelve month high of $37.00. The stock’s fifty day simple moving average is $27.23 and its 200 day simple moving average is $24.19.

Akero Therapeutics (NASDAQ:AKRO) last released its quarterly earnings results on Friday, August 9th. The company reported ($0.81) earnings per share for the quarter, topping the consensus estimate of ($0.90) by $0.09. As a group, sell-side analysts predict that Akero Therapeutics, Inc. will post -3.64 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages have commented on AKRO. HC Wainwright restated a “buy” rating and set a $50.00 price objective on shares of Akero Therapeutics in a research report on Tuesday, September 17th. Cantor Fitzgerald restated an “overweight” rating on shares of Akero Therapeutics in a research report on Thursday, June 20th. One research analyst has rated the stock with a hold rating and six have given a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $43.20.

Hedge Funds Weigh In On Akero Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Wellington Management Group LLP lifted its holdings in shares of Akero Therapeutics by 247.7% during the fourth quarter. Wellington Management Group LLP now owns 2,881,989 shares of the company’s stock worth $67,294,000 after purchasing an additional 2,053,028 shares during the period. Los Angeles Capital Management LLC acquired a new position in Akero Therapeutics during the 1st quarter worth about $211,000. Quattro Financial Advisors LLC grew its position in shares of Akero Therapeutics by 43,378.3% in the 1st quarter. Quattro Financial Advisors LLC now owns 10,000 shares of the company’s stock valued at $253,000 after buying an additional 9,977 shares during the last quarter. Bourgeon Capital Management LLC acquired a new stake in shares of Akero Therapeutics in the first quarter valued at about $383,000. Finally, Principal Financial Group Inc. raised its position in shares of Akero Therapeutics by 15.6% during the first quarter. Principal Financial Group Inc. now owns 13,766 shares of the company’s stock worth $348,000 after acquiring an additional 1,858 shares during the last quarter.

About Akero Therapeutics

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.